Mounjaro vs Ozempic

Mounjaro and Ozempic are both once-weekly prescription drugs for type 2 diabetes, but their Food and Drug Administration (FDA) labels differ. Mounjaro contains tirzepatide and is made by Eli Lilly. Ozempic contains semaglutide and is made by Novo Nordisk. Both labels include glycemic control and cardiovascular risk reduction. Ozempic's label also carries a chronic kidney disease indication; Mounjaro's does not.^1,2 Neither drug is FDA-approved for weight loss.

FDA-Approved Uses Side by Side

The current labels give Mounjaro and Ozempic overlapping diabetes indications with several differences in the populations covered.^1,2

Brand	Active ingredient	Manufacturer	FDA-approved indication(s)	Initial U.S. approval
Mounjaro	Tirzepatide	Eli Lilly and Company	Glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes. Reduction of major adverse cardiovascular events in adults with type 2 diabetes.	20221
Ozempic	Semaglutide	Novo Nordisk	Glycemic control in adults with type 2 diabetes. Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Reduction of sustained estimated glomerular filtration rate decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.	20172

Both labels cover improved glycemic control in type 2 diabetes. Mounjaro’s glycemic-control indication includes pediatric patients aged 10 years and older, while Ozempic’s indication covers adults.^1,2

Both labels also include cardiovascular risk reduction, but their wording differs. Mounjaro is indicated to reduce major adverse cardiovascular events in adults with type 2 diabetes. Ozempic’s cardiovascular indication applies to adults with type 2 diabetes and established cardiovascular disease.^1,2

The clearest label difference concerns chronic kidney disease. Ozempic is indicated to reduce several kidney and cardiovascular outcomes in adults who have both type 2 diabetes and chronic kidney disease. Mounjaro’s current label does not include that indication.^1,2

The Mounjaro vs Ozempic Indication Difference

Ozempic has the broader label when chronic kidney disease is part of your medical profile.² That does not establish that Ozempic is the right prescription for every person with kidney disease. It does give your physician a direct FDA-labeled indication to consider.

Mounjaro has a broader age range for glycemic control because its label includes adults and pediatric patients aged 10 years and older.¹ Ozempic’s glycemic-control indication is limited to adults.²

A label describes the uses the FDA has approved. It does not rank the drugs for your individual goals or account for your prior response, current medications, contraindications, or insurance coverage. Those details belong in the prescribing decision.

Label Question	Mounjaro	Ozempic
Type 2 diabetes glycemic control	Adults and pediatric patients aged 10 years and older	Adults
Cardiovascular risk reduction	Adults with type 2 diabetes	Adults with type 2 diabetes and established cardiovascular disease
Chronic kidney disease risk reduction	No current indication	Included for adults with type 2 diabetes and chronic kidney disease
FDA-approved for weight loss	No	No
Label verdict	Wider age range for glycemic control	Additional chronic kidney disease indication

Your diagnosis and treatment goals determine which label differences apply to you. The brand names alone cannot make that decision.

Shared Features Behind the Confusion

Mounjaro and Ozempic are frequently grouped together because both are injectable pens used once weekly for type 2 diabetes.^1,2 Both may also be discussed or prescribed off-label for weight loss, which means the use falls outside the approved indication on that brand’s label.

The similarities end before the active ingredient. Mounjaro contains tirzepatide, while Ozempic contains semaglutide.^1,2 They come from different manufacturers and have separate prescribing information.

The FDA labels also answer a different question from a head-to-head clinical trial. For the molecule mechanisms and the comparative trial evidence, see semaglutide vs tirzepatide. That distinction keeps the brand decision tied to the indications a prescriber can document.

FDA Dosing in the Mounjaro vs Ozempic Labels

Both drugs are injected once weekly, but the labeled starting doses, titration schedules, and maximum doses differ.^1,2 These are descriptions of the FDA labels. Your prescriber sets your dose based on your medical profile and response.

FDA Label Element	Mounjaro	Ozempic
Starting dose	2.5 mg once weekly	0.25 mg once weekly
Initial titration	Increase to 5 mg after 4 weeks	Increase to 0.5 mg after 4 weeks
Further increases	2.5 mg increments after at least 4 weeks on the current dose when additional glycemic control is needed	Increase to 1 mg after at least 4 weeks on 0.5 mg, then to 2 mg after at least 4 weeks on 1 mg when additional glycemic control is needed
Maximum adult dose	15 mg once weekly	2 mg once weekly
Maximum pediatric dose	10 mg once weekly for patients aged 10 years and older	No pediatric dosing under the current indication

The milligram values are not directly comparable because tirzepatide and semaglutide are different molecules. A lower number does not mean a weaker drug, and a higher number does not establish better results.

Neither label provides a conversion schedule for changing from one brand to the other. If you are considering a switch, your prescriber needs to set the new schedule rather than treating the labeled doses as equivalent.

Shared Warnings and Contraindications

Both labels carry a boxed warning about thyroid C-cell tumors observed in rodents.^1,2 The wording differs because each label describes its own active ingredient.

The Mounjaro label states:

> “In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.”¹

The Ozempic label states:

> “In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.”²

Both labels contraindicate use if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).^1,2 Both also list serious hypersensitivity to the active ingredient or product excipients as a contraindication.

Your family history and prior medication reactions need to be reviewed before either drug is prescribed. Those facts can remove both brands from consideration regardless of their indication differences.

Weight-Loss Evidence on the Right Comparison Page

Neither Mounjaro nor Ozempic is FDA-approved for weight loss.^1,2 Their labels establish uses related to type 2 diabetes and specific cardiovascular or kidney outcomes.

The weight-management brand questions belong to separate comparisons. The tirzepatide brand distinction is covered in Zepbound vs Mounjaro, while the semaglutide brand distinction is covered in Ozempic vs Wegovy.

If you want comparative weight-loss trial evidence, use the semaglutide vs tirzepatide comparison. If you are seeking an FDA-labeled weight-management treatment without type 2 diabetes, this diabetes-brand comparison cannot answer that prescribing question.

Coverage and Cost Factors

Neither FDA label states a price, and neither label tells you what your insurance plan will cover.^1,2 Your actual cost depends on the prescription, pharmacy, formulary, medical-necessity criteria, and any plan-specific authorization requirements.

Both brands have an FDA-approved type 2 diabetes indication, so your insurer can evaluate a diabetes diagnosis for either drug. Coverage may still differ because the labels do not cover identical populations or outcomes.

Consider a person with type 2 diabetes and chronic kidney disease. Ozempic’s label gives the insurer a specific kidney-disease indication to evaluate.² Mounjaro’s label includes glycemic control and cardiovascular risk reduction, but it does not include Ozempic’s chronic kidney disease indication.¹ That difference may lead the same insurer to request different documentation for each prescription.

A person with type 2 diabetes and no chronic kidney disease presents a different coverage question. Both labels support glycemic control, so the plan may focus more heavily on its formulary rules and prior authorization criteria. The labels do not predict which brand will have the lower out-of-pocket cost.

For a broader breakdown of the expenses and coverage variables, see GLP-1 cost. You need the exact prescription and your current plan terms before a price comparison becomes useful.

Physician-Guided Brand Decision

A physician can use the label differences to narrow the choice, but the label rarely makes the entire decision. Two common scenarios show how that process works.

If you have type 2 diabetes without established cardiovascular disease or chronic kidney disease, both brands carry a glycemic-control indication.^1,2 The labels do not declare a universal winner for that profile. Your physician can review your labs, treatment history, contraindications, medication list, and coverage before choosing a brand.

If you have type 2 diabetes and chronic kidney disease, Ozempic has an indication that directly matches both conditions.² Mounjaro does not carry that kidney indication under its current label.¹ That makes Ozempic’s label more directly aligned with the documented profile, although your physician still needs to consider the rest of your medical history.

The answer could change if either label gains a new indication or your insurer changes its formulary. Your own answer can also change as your labs, diagnoses, treatment response, or coverage change. The prescription needs follow-up rather than a one-time brand choice.

The Opt Take on Diabetes-Drug Selection

The label is the starting point for a prescription decision. Your physician still needs to interpret the indication against your labs, symptoms, medical history, current medications, and treatment goals.

At Opt Health, a physician reviews the full pattern before building a plan. Follow-up data then shows whether the plan is doing what it was intended to do. Treatment can be adjusted as your health and response change.

Bring your diagnosis, kidney history, cardiovascular history, medication list, and coverage details to a Mounjaro vs Ozempic discussion. That gives your physician enough context to move from a brand comparison to a monitored treatment plan.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.